Home
Neon Therapeutics

Neon Therapeutics Market Share Analysis for July 2026

at biontech we believe that every cancer patient’s treatment should be individualized. our vision is to provide patient-specific immunotherapies worldwide.

Health > Biotechnology and Pharmaceuticals

Domainneontherapeutics.com

Year Founded2015

Employees51 - 200

Annual Revenue$1M - $2M

Neon Therapeutics

Neon Therapeutics (including company regionals)

neontherapeutics.com

See more website traffic and engagement information

Neon Therapeutics Revenue up to July 2026 is 1M - 2M

revenue generated by Neon Therapeutics top domains

Neon Therapeutics top domains revenue over 3 years

Revenue for Neon Therapeutics top domains

neontherapeutics.com1M - 2M

See more with Sales Intelligence

Total visits to Neon Therapeutics's top domains

Understand Neon Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Neon Therapeutics's top domains

Analyze Neon Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Neon Therapeutics's top domains

See how Neon Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Neon Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Neon Therapeutics

These are the website technologies, by industry, used by Neon Therapeutics top domains

Widget (5)

Twemoji

Content Management System (3)

WordPress

Audio Video Media (2)

YouTube

Advertising (1)

DoubleClick

More Technologies

7

See all

News & Signals from Neon Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNeon Therapeutics Inc sold assets to BioNTech US Inc. in the amount of $70M on Jan 1st '20.Inbio Ventures contributed to the $70m Series B funding raised for the development of drugs BioNTech acquired from Neon Therapeutics through its acquisition of the company in January 2020.

NewsAng left Neon Therapeutics Inc as Chief Business Officer on Jan 1st '19.Dr. Ang joined Vor Biopharma in 2019 from Neon Therapeutics (acquired by BioNTech) where, as Chief Business Officer, he helped oversee the company's transformation from pre-seed stage through to a successful NASDAQ IPO.

NewsNeon Therapeutics Inc has issues with violations of the Securities Exchange Act of 1934.The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Neon, its Board of Directors (the “Board”), BioNTech, and Merger Sub, is captioned Franchi v. Neon Therapeutics, Inc., Case No. 1:20-cv-00482 (D. Del.).